top of page

Invion (ASX IVX), Research and Coverage

invion-limited

Invion Limited (ASX: IVX) is a clinical-stage drug developer based in Melbourne. It holds a perpetual, exclusive global licence to develop Photosoft, a light-activated drug technology, for a list of cancers and other diseases (ASX announcement, 3 December 2025). Its lead drug candidate, INV043, has completed Phase I treatments in a skin cancer trial, and Invion is planning Phase II. Preliminary Phase I findings from 14 patient readouts showed no serious adverse events and a 79 per cent disease control rate across treated lesions (ASX announcement, 19 October 2026). The loss after tax was A$5.63 million in the year to 30 June 2026 (annual report, lodged 26 August 2026). Cash was A$512,000 at 30 September 2026 (Appendix 4C, lodged 29 October 2026). Samso had published 3 pieces on the company at 19 November 2026.

ASX code: IVX. Full legal name: Invion Limited. Executive Chairman and Chief Executive Officer: Thian Chew. The annual report, lodged 26 August 2026, names the other directors as Alan Yamashita and Paul Field, both non-executive, and Melanie Leydin, a non-executive director who was also company secretary and chief financial officer. Invion held A$512,000 in cash at 30 September 2026 (quarterly report and Appendix 4C, lodged 29 October 2026).

What Invion is developing

Invion is developing Photosoft, a family of compounds for photodynamic therapy. In this treatment a drug called a photosensitiser is applied to a tumour and then lit with light of a set wavelength. The light switches the drug on, and it produces reactive oxygen that destroys tumour cells (ASX announcement, 20 October 2026).

The lead drug candidate is INV043. In the skin cancer trial it is applied to the skin as a topical formulation. Red light at 660 nanometres activates the treatment. Violet light at 405 nanometres makes treated lesions glow so they can be seen. The company says the glow signals support the theragnostic potential of INV043, meaning one compound used both to treat and to show a lesion (ASX announcement, 21 April 2026).

Invion holds the technology under licence. In December 2025 it secured a perpetual, exclusive global licence for a list of "Agreed Indications", which shareholders approved on 29 May 2026. The list includes anogenital, lung, oesophageal, non-melanoma skin and brain cancers, all animal cancers, HPV and non-cancer eye diseases (ASX announcement, 3 December 2025, and annual report, lodged 26 August 2026).

The licensors are controlled by Photosoft's inventor, Michael Honsue Cho. Invion pays no upfront cash. Consideration is up to 36,705,966 Invion shares in three milestone tranches and a 10 per cent royalty on future net sales. The licensor also receives 20 per cent of any amount Invion receives for assigning or sub-licensing its rights.

The first tranche of 12,235,322 shares was issued on 12 June 2026 (annual report, lodged 26 August 2026). The second is due when Invion or a sublicensee doses the first patient in a Phase II trial in a licensed cancer under an IND, the application the United States Food and Drug Administration requires before a new drug is tested in people there. The third needs a second such trial in another licensed cancer, or a Phase III trial (ASX announcement, 3 December 2025).

RMW Cho Group Ltd was the largest shareholder at 10 August 2026, with 11.20 per cent (annual report). An Appendix 3Y lodged 18 November 2026 lists RMW Cho Group Ltd, RMWC Pty Ltd and Honsue Cho as associates of Thian Chew, and counts their shares among his indirect interests.

Invion skin cancer trial

The annual report describes an open-label Phase I/II trial, meaning patients and doctors know which treatment is given, of topical INV043 in non-melanoma skin cancer in Queensland. Phase I tests mainly safety in a small group. Phase II looks more closely at dose and effect. The trial received Human Research Ethics Committee approval in the 2025 financial year (annual report, note 11, lodged 26 August 2026).

The trial began with squamous cell carcinoma, or SCC. In April 2026 its Safety Review Committee, the panel that checks safety data before a trial moves on, approved expanding it to basal cell carcinoma, or BCC, which the company says makes up about 80 per cent of skin cancers (ASX announcement, 21 April 2026).

On 19 October 2026 Invion said it had completed treatments and closed recruitment for Phase I. Preliminary, unaudited findings from 14 patient treatment readouts showed no serious adverse events and no dose-limiting toxicities. A dose-limiting toxicity is a side effect severe enough to stop a dose being raised. Eight mild to moderate adverse events, such as a mild headache, were assessed by the committee as "not related" or "unlikely related" to the treatment (ASX announcement, 19 October 2026).

Tumour responses were assessed with calliper measurements that the company describes as consistent with RECIST 1.1 principles. RECIST is a standard way of scoring changes in tumour size. The company reports a 79 per cent disease control rate across SCC and BCC lesions, with one complete response, and calls these "encouraging efficacy signals". Under RECIST, disease control usually counts lesions that disappeared or shrank, plus lesions whose size stayed within set limits. The announcement does not give its own definition. A complete response means the lesion disappeared. The 79 per cent is a share of treated lesions, and the announcement does not say how many lesions were treated (ASX announcement, 19 October 2026).

The company believes the preliminary findings are enough to meet the trial's primary safety endpoints, the main safety measures the trial set out to test. It states that results will be finalised only after 12 months of patient follow-up and an independent audit. It is planning a Phase II trial that includes work to find the best dose and may target advanced skin cancers (ASX announcement, 19 October 2026).

Invion anal cancer program and partners

Invion's second planned clinical program is in anogenital cancers, which include anal, vulvar and penile cancer. On 20 August 2025 Invion announced that the FDA had granted Orphan Drug Designation to INV043 for anal cancer. This status is given to drugs for rare diseases. The company lists seven years of exclusive United States marketing rights after approval, possible tax credits and fee waivers, and the chance of a faster path to market (ASX announcement, 20 August 2025).

The annual report says preclinical work at the Peter MacCallum Cancer Centre, known as Peter Mac, supported the FDA's decision. Preclinical means laboratory and animal studies before any testing in people. In mouse models of anal squamous cell carcinoma, INV043 combined with an immune checkpoint inhibitor gave about 80 per cent tumour control, against about 12 per cent for the inhibitor alone (ASX announcement, 20 August 2025). An immune checkpoint inhibitor is a drug that releases a brake that some cancers place on the immune system. Invion and Peter Mac are preparing a clinical trial of INV043 with these drugs. The company describes the trial as co-sponsored by Peter Mac (ASX announcement, 19 November 2026) and as upcoming (quarterly report, lodged 29 October 2026).

Partners fund other programs. Under the Protect and SANGMYUNG agreements Invion retains all rights to Photosoft.

  • Hanlim Pharm (South Korea). Funding work towards an Australian trial of intravenous INV043, which Hanlim calls HL270, in oesophageal cancer. The program is put at up to about A$2 million, supported by a Korea Drug Development Fund grant (ASX announcement, 23 December 2025). Invion's revenue of A$384,707 in the year to 30 June 2026 came from this agreement (annual report, note 6).
  • Protect Animal Health (Taiwan). Funding and running studies of Photosoft compounds for cancer in companion animals (ASX announcement, 21 October 2025).
  • SANGMYUNG Innovation (South Korea). Funding preclinical studies in wet age-related macular degeneration, an eye disease that causes vision loss (ASX announcement, 19 May 2026).

Invion cash, funding and money owed

Invion reported a loss after tax of A$5.63 million in the year to 30 June 2026, against A$8.81 million a year earlier. Cash was A$592,311 at 30 June 2026. Net assets were A$5.32 million (annual report, lodged 26 August 2026).

Current liabilities at 30 June 2026 were A$2.85 million, giving net current liabilities of A$2.15 million. The directors note that this includes A$408,742 of salaries and fees owed to current directors, which are not payable to third parties, and convertible note and derivative liabilities that need no cash payment. Without these items, net current liabilities are about A$619,052. The financial report notes a material uncertainty that may cast significant doubt on the group's ability to continue as a going concern. In support of the going concern basis the directors cite R&D tax incentive financing, the ability to scale down research, possible equity raising and possible director loans (annual report, lodged 26 August 2026).

In the September 2026 quarter Invion paid A$338,000 for research and development and A$189,000 for administration and corporate costs. It received A$545,000 of R&D tax incentive, the Australian Government program that refunds part of eligible research spending. Net operating cash flow was a positive A$18,000. It received A$392,000 of borrowings and repaid A$400,000. Item 8.5 shows 28.44, which is cash divided by the quarter's positive operating cash flow. The form's own note says the item should read N/A when operating cash flow is positive (quarterly report and Appendix 4C, lodged 29 October 2026).

On 29 September 2026 Invion announced loans of up to A$200,000 each from Thian Chew and Alan Yamashita. They are unsecured, carry 8 per cent interest and mature four months after each advance (ASX announcement, 29 September 2026). The Appendix 4C lists no loan facilities and does not refer to these loans.

Invion announced two funding agreements on 21 October 2026. It expects them together to cover up to about 85 per cent of its clinical trial costs. Point8 Capital committed up to A$25 million, paying half of each invoice from the contract research organisations that run the trials. In return Invion is to grant Point8 11,055,313 options at A$0.03639. They can be exercised only as Point8 provides funding and only once a drug candidate reaches Phase III. Rockford Capital committed a secured facility of up to A$7.5 million over the 2027 and 2028 financial years, lent against expected R&D tax refunds at 16 per cent interest. The company states there is no assurance the funding will be received or will not be withdrawn (ASX announcement, 21 October 2026).

The notice for the annual general meeting of 25 November 2026 lists resolutions to approve the Point8 options and the Rockford arrangement fee shares (notice of meeting, lodged 23 October 2026). Invion announced that Melanie Leydin would retire on the meeting date and that Philip Wood would join the board from 26 November 2026 (ASX announcement, 11 November 2026).

Every Samso piece on Invion

3 published pieces as at 19 November 2026, grouped by Samso product. Newest first in each group. Dates are Perth dates.

Samso News

Questions people ask about Invion (ASX IVX)

What is the Invion share price? The ASX website shows the IVX share price. This page lists Samso's coverage and has no live price.

What is the latest announcement from Invion? As at 19 November 2026 the newest item on the ASX list was the R&D tax incentive refund of A$502,675, lodged on 19 November 2026.

What has Invion's skin cancer trial shown? Preliminary, unaudited Phase I findings from 14 patient readouts showed no serious adverse events and a 79 per cent disease control rate across treated lesions, with one complete response (ASX announcement, 19 October 2026).

Is Invion worth looking at? This page gives no buy, sell or hold call, price target or valuation. Invion is a clinical-stage drug developer. The sections above give its trial results, funding and going concern note with the documents they come from. Samso had published no research workup on Invion at 19 November 2026.

Disclosure

Samso holds no shares in Invion at 17 November 2026.

This page is general information only.

Depth over hype.

Samso company research pages are independent research commentary for general information only. Nothing on this page is financial product advice, and it does not take into account any reader's objectives, financial situation or needs. Figures are drawn from public sources believed reliable at the stated dates but are not guaranteed, and market-sensitive numbers change daily. Samso or associated parties may hold positions in, or have commercial arrangements with, companies mentioned. Seek professional advice before making investment decisions. © Samso 2026, samso.com.au

Page last reviewed 19 November 2026.

bottom of page